Cancer of Esophagus
29
5
8
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.4%
1 terminated out of 29 trials
91.7%
+5.2% vs benchmark
3%
1 trials in Phase 3/4
9%
1 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (29)
Real-time Activity Monitoring to Prevent Admissions During RadioTherapy
Mayo Clinic Upper Digestive Disease Survey
Onco-primary Care Networking to Support TEAM-based Care
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Tempus Priority Study: A Pan-tumor Observational Study
Wet Heparinized Suction for Abdominal Cancer
Genomic Testing and Resulting Medical Decisions
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)
Radiogenomics in Aerodigestive Tract Cancers
Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1
Surgery As Needed for Oesophageal Cancer - 2
Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer
Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
Impedance Spectroscopy in Esophageal Cancer
GLIM-defined Malnutrition Criteria for Postoperative Outcomes in Patients With Esophagogastric Cancer
Impact of Cancer Therapy on Myocardial Function in Patients With Esophagus Cancer